Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early ivabradine heart-rate control after primary PCI in STEMI
ChiCTR-IPR-17013125Phase 4Not yet recruiting
- Sponsor
- Shenzhen Sun Yat-sen Cardiovascular Hospital
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ivabradine in myocardial infarction (MI) (2 arms), sponsored by Shenzhen Sun Yat-sen Cardiovascular Hospital. Primary endpoints: Left ventricular end-diastolic volume, Left ventricular end-systolic volume and 2 more. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
ivabradine
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR-IPR-17013125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17013125.